Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CombinatoRx has said that its rheumatoid arthritis drug failed to meet the endpoint in a phase II trial.
Subscribe to our email newsletter
The drug known as CRx-139 is a synergistic combination of 3mg prednisolone and the antidepressant paroxetine. CRx-139 did show statistical significance on multiple other endpoints which require further analysis, the company said.
This trial was designed to determine the effectiveness of CRx-102 compared to 3mg of prednisolone and to examine 3mg of prednisolone alone.
“This trial confirms that the strong clinical activity previously reported with CRx-102 should not be attributed to the effect of its low dose prednisolone component alone,” said Alexis Borisy, president and CEO of CombinatoRx.
“We are pleased to have this additional validation of our combination sciences approach to selective steroid amplification, and we look forward to rapidly advancing CRx-102 as our lead dissociated steroid combination for the treatment of RA and OA.”